Survival among Patients with Pancreatic Adenocarcinoma, California, 1994-2000

Rosemary D. Cress, DrPH
Lisa C. Clarke, MS
California Cancer Registry
Daixin Yin, MS, CCR
Richard Bold, MD, UC Davis, Dept. of Surgery
Elizabeth A. Holly, PhD, UCSF Dept. of Epidemiology
Objective

• Survival after diagnosis with pancreatic cancer is notably short. However there have been few population-based analyses of factors that influence survival.
• The purpose of the current study was to evaluate survival of patients diagnosed in California with adenocarcinoma of the pancreas by demographic and tumor factors.
Methods

- Through the California Cancer Registry we identified all California residents diagnosed with invasive pancreatic adenocarcinoma between January 1, 1994, and December 31, 2000.
- Demographic, tumor and treatment information was extracted from the CCR, and socioeconomic status (SES) was assigned based on census tract of residence.
Results

- A total of 10,612 eligible patients were identified.
- 63% were age 65 or older
- 73% white, 8% black, 11% Hispanic, 8% API
- Over half were diagnosed with metastatic (SEER SS=remote) disease
Results

- 15.8% of patients received resection
- % with resection increased from 14.7% in 1994 to 18.7% in 2000.
- Patients were more likely to have resection if they were younger, had smaller tumors, well-differentiated tumors, tumor in the head of the pancreas, and higher SES.
- Blacks and low SES patients were somewhat less likely to have surgery.
Non-resected patients

- Median survival was 3 months for patients with no surgery.
- Among those with no surgery, longer median survival was observed for patients with localized disease, well-differentiated tumors and negative lymph nodes.
- Median survival increased slightly with each quintile of SES (p for trend < 0.001).
Results

- Median survival was 13 months for those with surgery.
- Metastatic disease at diagnosis, poorly-differentiated tumors, positive lymph nodes and lack of adjuvant therapy were associated with increased risk of death among patients with surgery.
Results

- Survival increased with each quintile of SES:
  - 1 11.3 months
  - 2 11.8 months
  - 3 15.1 months
  - 4 13.8 months
  - 5 15.0 months

- p for trend < 0.002
Hazard ratios for resected patients

- Age >=65 vs. <65: 1.16 (1.04-1.29)
- NH Black vs. NH White: 1.02 (0.80-1.21)
- Remote stage vs. local: 2.00 (1.56-2.57)
- Poorly diff. vs. well-diff: 2.00 (1.67-2.41)
- No adjuvant therapy: 1.52 (1.36-1.70)
- Lower SES vs. high: 1.10 (0.99-1.23)
Limitations

- Completeness of adjuvant treatment information in the CCR
- Completeness of follow-up
- No pathologic review
Conclusions

- This study is the largest population-based study to date to explore survival from pancreatic cancer among all age groups in a racially diverse population.
- Median survival was shorter than that reported from other series.
Conclusions

- Race/ethnicity did not have a significant effect on survival, however patients residing in poor neighborhoods were less likely to receive surgery and somewhat less likely to survive this disease.